Ballot measures · California statewide proposition

Proposition 38: Authorizes Bonds for Immunology Medical Research

22 sources, dated 2026-04-05 – 2026-10-20· last searched 2026-10-28

Official title: Authorizes Bonds for Immunology Medical Research. Initiative Statute.

Overview

Synthesized 2026-10-28 in an operator-run Claude session from 18 sources dated 2026-04-05 to 2026-10-20. Machine-written; numbers link to the sources below.

Proposition 38, the California Immunology Research and Cures Initiative, is an initiative statute that would authorize $8.4 billion in state general obligation bonds for immunology and immunotherapy research, repaid from the General Fund ^11,16,7. Half of the bond money would go to a single nonprofit research institute selected by the Department of Public Health under fixed criteria, including a University of California affiliation, and the other half to project grants awarded by a council whose core members are appointed by seven UC campus chancellors ^11,16. At least $4.2 billion must go to research on cancer, heart disease and Alzheimer's, state administration is capped at 2 percent, recipients must pay the state 10 percent of revenues from resulting discoveries until bond costs are repaid, and funded drugs must be sold in California at least 20 percent below the national average price ^11,16. The Legislative Analyst's Office estimates a General Fund cost of $500 million to $600 million a year for about 20 years, with offsetting revenue it calls uncertain but potentially significant and possibly decades away ¹⁶. Supporters, including the Alzheimer's Association, the Michael J. Fox Foundation, the Kidney Cancer Association and other patient groups, argue the measure would stabilize research amid federal funding cuts and is designed to pay for itself ^21,8,17. Opponents, including former NIH official Robert Kaplan, the League of Women Voters of California, and the editorial boards listed by CalMatters, argue bond-financing a single research field is the wrong approach and that the measure is unlikely to repay its cost ^21,12,9. CalMatters reported in July 2026 that the institute criteria very likely fit only the California Institute for Immunology and Immunotherapy (CIII), whose co-founder and board chair Gary K. Michelson wrote and is the chief funder of the measure; the Yes campaign said the language is not uniquely tailored but later said CIII will 'very likely' qualify ^14,2,5. The most recent reporting, from October 2026, says CIII had three employees as of September and that the measure exempts it from state public-records and open-meeting laws ^2,3. As of October 22, 2026, support committees reported $71.2 million in contributions and the opposition $11,990 ¹⁹.

Record

The initiative (AG No. 25-0026A1) was filed and financed by Dr. Gary K. Michelson, entered circulation on January 2, 2026, and qualified for the November 3, 2026 ballot in June-July 2026.^18,17,11
The measure's text requires the selected institute to have existed by January 1, 2025, to have a UC affiliation with a campus health system exceeding 35,000 inpatient admissions and 3.5 million outpatient visits a year, to hold a 200,000-square-foot site by January 1, 2026, and to have $250 million in identified philanthropy plus $50 million commitments for vaccine and microbiome programs.¹¹
The text names UCLA to receive an offer to collaborate on clinical trials in every grant and makes UCLA's appointee the council's first chair; it declares the selected institute is not a public agency under state law.¹¹
UCLA and CIII signed their affiliation agreement in August 2024; UCLA Health CEO John Mazziotta told UC Regents on September 16, 2026 that CIII had three employees and had spent $20 million.²
Through October 22, 2026, the two Yes on 38 committees sponsored by the Michelson Center for Public Policy reported $71,229,216 in contributions; the No on Proposition 38 committee reported $11,990.¹⁹
Governor Newsom signed SB 895 on September 30, 2026, which places a separate research bond (reported as $7.5 billion) for a new state science foundation on the 2028 ballot.^8,6,3

Stated positions

Supporters (Alzheimer's Los Angeles, ALS Association, Kidney Cancer Association and others, in the official ballot argument) say Prop. 38 is designed to pay for itself 'with no net cost to the state or taxpayers' through the 10 percent revenue return.²¹
Yes on 38 spokesperson Claudia Briggs said in July 2026 the measure was written 'to ensure a highly qualified nonprofit could receive funding' and is not uniquely tailored to CIII.¹⁴
Yes on 38 spokesperson Robin Swanson said in September-October 2026 that it is 'very likely' CIII will qualify for half the funds, that other institutes will qualify for grant funds, and that the Department of Public Health makes the final decision.^2,5
Robert Kaplan, the official ballot opponent, argues research priorities should be set by scientific review rather than ballot measures and that bonds are inappropriate for research; in an April 2026 Daily Bruin interview, before the measure qualified, he said he would vote for the initiative while calling rapid repayment 'completely unrealistic.'^21,22
The League of Women Voters of California recommends a No vote.¹²
The Michael J. Fox Foundation and the Kidney Cancer Association state that they support the measure.^8,17

Arguments for

Immunotherapy has already transformed treatment for some cancers, and sustained funding could produce treatments and cures for cancer, Alzheimer's, Parkinson's, heart disease and other conditions. — Alzheimer's Los Angeles, Michael J. Fox Foundation, Kidney Cancer Association, Prostate Cancer Foundation, Laurie Adami^21,8,17,3
Federal research funding cuts and uncertainty have disrupted research and slowed cancer trials, and a stable state funding source would fill that gap. — Yes on 38 campaign, Kidney Cancer Association (Dr. Brian Shuch), Blood Cancer United^21,5,17,22
The measure is designed to pay for itself: 10 percent of licensing revenue goes to the state to offset bond costs, and funded treatments must be sold to Californians at a 20 percent discount. — Yes on 38 campaign, Kidney Cancer Association^21,17
Accountability provisions, including a 2 percent administrative cap, public disclosure, independent audits and a bar on for-profit grantees, protect taxpayers. — Yes on 38 campaign²¹
The detailed institute criteria ensure the selected institute is focused on immunology, already well resourced, has adequate facilities, and is closely tied to a UC campus so it can begin work immediately. — Claudia Briggs, Yes on 38¹⁴
Basic biomedical research is a public good that markets underfund, and one major therapy could outweigh the bond's cost; the discount and administrative cap respond to criticisms of the stem cell program. — Hoover Institution (presenting the supporting case)¹⁸

Arguments against

Bond borrowing is a poor way to fund research: it commits $500 million or more a year for decades, displaces other General Fund spending, and research returns are slow and uncertain. — Robert Kaplan, League of Women Voters of California, Dan Walters (CalMatters)^21,12,6
Earmarking billions for one scientific field by ballot measure bypasses expert priority-setting and locks in funding regardless of future needs. — Robert Kaplan, League of Women Voters of California, Dan Walters (CalMatters), Judy Heiman^21,12,6,3
The claim that it will pay for itself is speculative; the stem cell bonds returned little to the state. — Robert Kaplan, Dan Carson, League of Women Voters of California, Hoover Institution^21,3,12,18
The criteria appear written so that half the money, about $4.2 billion, goes to one institute co-founded by the measure's chief backer, excluding other California research institutions. — No on 38 campaign (David Panush), Sarah Hill (Cal State Fullerton), Robert Kaplan, Marianne O'Malley^5,14,13,3,10
The likely recipient institute is not ready: it had three employees as of September 2026 and its facility is not expected to be complete until at least late 2028. — CalMatters reporting, David Panush, No on 38^2,5
Exempting the institute from public-records, open-meeting and political-reform laws means taxpayers cannot track how the money is spent. — Marianne O'Malley^3,2
The California price discount could lead companies to prioritize sales in other states. — Robert Kaplan^21,22

Where sources disagree

Repayment period: the LAO's ballot analysis, the official summary, CalMatters' voter guide, LAist's guide and the League estimate about 20 years at $500 million to $600 million a year, while the official argument against, CalMatters reporting, Dan Walters, Hoover and the Daily Bruin cite about $500 million a year for about 25 years (about $12.5 billion), attributing it to the LAO; the 25-year figure appears to come from an LAO estimate dated 2025, before the measure qualified.^{16,7,9,10,12,21,14,6,18,22}
Whether only one institute qualifies: CalMatters and a UCLA spokesperson say only CIII meets the criteria, and the campaign's Swanson called that 'very likely,' while the campaign's Briggs said the language is not uniquely tailored and Swanson said 'it's not accurate to say that only one institute would qualify for funds under this measure,' referring to the grant half.^14,2,5
Total cost: KQED reports about $4 billion in interest on top of the $8.4 billion bond, while the LAO describes the total cost as about 10 percent more than paying cash after adjusting for inflation.^3,16
Stem cell bond returns: Hoover says the state received on the order of a few hundred thousand dollars from funded inventions by the early 2020s, while former LAO analyst Dan Carson told KQED the state received $16 million.^18,3
Robert Kaplan's position: in April 2026 he told the Daily Bruin he would vote for the initiative, while the October voter guide carries his signed argument urging a No vote.^22,21

What we could not find

No text of the newspaper editorials (Orange County Register, San Diego Union-Tribune, Sacramento Bee, San Francisco Chronicle) was collected; only their opposition is listed by CalMatters.
No statement or materials from the No on 38 campaign or California Health Policy Strategies were collected directly; their arguments appear only through news quotes.
No materials from the Yes on 38 campaign website or the California Institute for Immunology and Immunotherapy itself were collected; the campaign's case comes from the ballot argument, supporter organizations and news quotes.
No independent analysis was collected of the number of institutes that could meet each criterion beyond CalMatters' reporting.
No itemized list of top donors was collected; only committee-level totals.
The American Association of Immunologists endorsement page returned an error (HTTP 404).

Questions to consider

Which organizations besides CIII, if any, could meet every eligibility criterion in Section 130353, and what would happen under the criteria-modification fallback?
How likely is the 10 percent revenue share to offset the bond's cost, given the stem cell bond experience?
How would the 20 percent California price discount be calculated and enforced once a drug is licensed to a manufacturer?
What oversight applies to the selected institute given its exemption from public-records and open-meeting laws?
How does Prop. 38 compare with the broader state research bond scheduled for the 2028 ballot?
Is the repayment period about 20 years or about 25 years, and what is the total cost in today's dollars?

Text analysis

Written 2026-10-28 in an operator-run Claude session from 2 primary texts^10,20. An evaluative machine reading: check each point against its quoted evidence.

Coverage: Full Text of Proposed Laws for Proposition 38 from the Official Voter Information Guide (S1): Sections 1-3 (title, findings, purpose), Section 4 adding Health and Safety Code Division 110.5, Sections 130350-130364 (research program) and 130370-130385 (bond act), and Sections 5-7 (severability, liberal construction, amendment). The text is complete. The stored copy is converted from the PDF, so the italics marking new language are lost (all of the measure is new language, so nothing is struck out), and the file also holds the end of Proposition 37 and the start of Proposition 39 from adjacent pages, which were disregarded.

Drafting: Mixed

The bond-act chapter (130370-130385) follows the standard California general obligation bond template and is clear and internally consistent. The research-program chapter is detailed and mostly precise, with defined terms, numeric earmarks, reporting and audit duties, and specific royalty and pricing formulas. Weaknesses are in completeness and balance of discretion: the institute-eligibility criteria are fixed to past dates and numeric thresholds that define a closed class, while the fallback lets the department rewrite them under a loose 'minimum modification' standard; the price-discount and revenue-sharing obligations have no stated enforcement mechanism or remedy; the purpose clause promises a 98 percent research-spending requirement the operative text does not impose on the institute; and the selected institute is exempted from state transparency law while also being given roles in grant decisions, licensing approval and bond-issuance requests. Severability, liberal construction and a two-thirds amendment clause are routine for California initiatives; the bar on amending the allocation of bond proceeds is a stronger lock than usual.

Findings

beneficiaryhigh impactHealth and Safety Code 130353(a)(1)-(4)
Half of all bond moneys (130352(b)(1)) go to one institute that must meet criteria fixed to dates before the election: existence and founding purpose as of January 1, 2025, a UC affiliation agreement and bylaws adopted by January 1, 2025, and a 200,000-square-foot site owned or leased as of January 1, 2026. Because these dates have passed, no new organization can become eligible; the eligible class is closed at enactment. The text does not name any institute, and it does not show by itself how many existing organizations meet every criterion.
“that was in existence as of January 1, 2025, and that was founded for the primary purpose of, and specializes specifically in, conducting research in the fields of immunology and immunotherapy”¹⁰
beneficiaryhigh impactHealth and Safety Code 130353(a)(2)(C)
The institute's UC partner campus must exceed specific patient-volume thresholds. This limits eligibility to institutes affiliated with UC campuses whose health systems exceed both figures, which may be a small number of campuses. Which campuses qualify is a factual question the text does not answer.
“The campus health care system has a hospital and clinic volume of greater than 35,000 inpatient admissions and 3,500,000 outpatient visits each year.”¹⁰
expansive languagehigh impactHealth and Safety Code 130353(b)(2)
If no institute both qualifies and is willing to sign, the department must rewrite the eligibility criteria itself. The only limits are 'minimum amount of modification necessary' and furthering the chapter's purposes, with no process, public notice, or review specified. This gives the department wide discretion over who receives about $4.2 billion and leaves open which criteria may be relaxed first.
“shall be the minimum amount of modification necessary to identify an eligible nonprofit medical research institute and shall further the purposes of this chapter”¹⁰
conflicthigh impactHealth and Safety Code 130363(a)
The institute receiving about $4.2 billion in public funds is exempted 'notwithstanding any other provision of law' from state law applicable to public agencies, expressly including Government Code Division 10 of Title 1 (public records), Article 9 of Chapter 1 of Part 1 of Division 3 of Title 2 (state open meetings), and Title 9 (the Political Reform Act, which 130363(b) names). Public accountability for the institute rests on the annual report (130359), the Controller's review of its audit (130361(a)), and the oversight committee (130362).
“the institute shall not be deemed a public agency for any purpose under state law”¹⁰
gaphigh impactHealth and Safety Code 130358(b)
Recipients that license or sell a funded drug must ensure it is sold in California at least 20 percent below the national average price. The text does not say who calculates the national average, what data source is used, whether the obligation binds downstream licensees and manufacturers who are not recipients, or what penalty or remedy applies if the price is not met. No agency is assigned to enforce it.
“at a price that is at least 20 percent below the national average price, calculated by excluding California”¹⁰
special clausemedium impactHealth and Safety Code 130353(a)(6)-(7)
Eligibility requires specific pre-existing philanthropic commitments, $250 million in identified funding plus two $50 million commitments for two named program types. Requirements this specific are unusual in a funding-eligibility test and further narrow the eligible class to organizations that already have these particular commitments.
“not less than fifty million dollars ($50,000,000) to support a rapid vaccine development program and not less than fifty million dollars ($50,000,000) to support a microbiome research program”¹⁰
enforcementmedium impactHealth and Safety Code 130353(c)(2)
The institute's funding agreement is reviewed only every five years, and termination is allowed only if non-compliance 'substantially and materially frustrates' the chapter's purposes, after notice and a chance to cure. No other remedy (suspension, clawback, withholding of disbursements) is stated, so the department has limited tools between reviews.
“the failure substantially and materially frustrates the purposes of this chapter”¹⁰
gapmedium impactHealth and Safety Code 130353(e)(2)
The measure appropriates $100 million from the General Fund as start-up loans to the institute. Repayment is due within 12 months of the related bond draw, or otherwise at a time the Treasurer finds practicable, with no outside deadline, interest, or provision for what happens if bonds are never drawn.
“as soon thereafter as is practicable as determined by the Treasurer”¹⁰
expansive languagemedium impactHealth and Safety Code 130354(a)(1)(A)
The institute may spend its half on research it conducts or research it 'otherwise direct[s],' so it may pass funds to other parties. The text sets no selection process, peer review, or conflict rules for such subawards comparable to those the council must follow under 130356.
“or is otherwise directed by the institute”¹⁰
gapmedium impactSection 3(j); Health and Safety Code 130354(a)(3)
The purpose clause describes a 98 percent research-spending requirement, but the operative text caps only the administrative costs of the department, council, committee and Controller at 2 percent (130354(a)(3)). No operative provision limits the institute's own overhead; grants under 130357(g) cap indirect costs at 20 percent, but that applies to council grants, not the institute's half. Purpose statements generally do not create binding duties.
“a requirement that 98 percent of all funds be spent for costs related to medical research and development of cures”¹⁰
beneficiarymedium impactHealth and Safety Code 130352(b)(2); 130355(b)
The grant half is open only to institutions represented on the council. Seven members are appointed by the chancellors of seven named UC campuses; those seven appoint the 10 to 15 other members. Institutions not given a council seat by that executive committee cannot apply, so the council controls both who can apply and who wins.
“disbursed to those public and nonprofit universities and other nonprofit research institutions represented on the council”¹⁰
beneficiarymedium impactHealth and Safety Code 130357(e); 130355(d)(2)
Every grant agreement must offer UCLA, named in the text, a chance to participate in the grant's clinical trials, and UCLA's appointee is designated the council's first chairperson. No other campus receives a comparable named right.
“offer the University of California, Los Angeles the opportunity to substantially participate in and collaborate on any clinical trials conducted as part of the funded research”¹⁰
othermedium impactHealth and Safety Code 130356(e)(2); 130357(d); 130358(e)(2)
Beyond its own half, the selected institute must be consulted on final grant decisions, must be offered participation in every grant-funded project (130357(d)), serves as 'clearinghouse and approval center' for all commercialization agreements (130358(e)(2)(A)), and takes primary negotiating responsibility where it collaborates (130358(e)(2)(C)). These roles give one private entity influence over the whole program, including grants to potential competitors. The text does not say how disagreements between the council and the institute are resolved.
“The council shall confer with the institute selected by the department pursuant to Section 130353 in making final decisions regarding the funding of grant proposals”¹⁰
special clausemedium impactHealth and Safety Code 130363(b)(1)-(2)
The Political Reform Act applies to the council, but with exceptions: members are barred only from decisions involving their own employer, may vote on grants to competitors in the same field, and may vote on research into diseases affecting themselves or family. Because grant applicants must be council-represented institutions (130356(a)), members will routinely decide on grants to each other's institutions.
“a member may participate in a decision to approve or award a grant or contract to an entity in the same field as their employer”¹⁰
special clausemedium impactHealth and Safety Code 130363(d)
Government Code Section 1090, the general bar on officials having a financial interest in contracts they make, applies to council grants only if the grant benefits the member's own entity and the member fails to recuse. This narrows the usual prohibition to a recusal rule.
“Section 1090 of the Government Code shall not apply to any grant or contract made by the council except where both of the following conditions are met”¹⁰
enforcementmedium impactHealth and Safety Code 130376(a)
The trigger for bond issuance is a written request from the private institute; the department then 'shall request' the finance committee to issue bonds, and the committee decides whether issuance is necessary or desirable. The text does not say whether bonds may be issued for the council's grant half without an institute request.
“Upon written request by the research institute selected by the State Department of Public Health pursuant to Section 130353”¹⁰
ambiguitymedium impactHealth and Safety Code 130358(a)(1)
Recipients owe the state 10 percent of 'all revenues derived' from IP arising from funded research, even if the research was only partly state-funded. 'Revenues' is not defined (gross or net, before or after any shares owed to partner institutions), and the text does not say how 'arise from research funded under this chapter' is determined when funding is mixed. The answer affects how much the state recovers.
“calculated without regard to whether the research that gave rise to the intellectual property rights was funded wholly or only in part by research funds”¹⁰
durationmedium impactSection 7
A two-thirds legislative vote to amend only in furtherance of the act's purposes is common in California initiatives. This clause goes further: the Legislature cannot change the 50/50 allocation, the single-institute structure, or permitted uses at all, so any such change would require another vote of the people.
“no such statute shall amend the provisions of this act regarding the allocation and disbursement of bond proceeds or the purposes for which bond proceeds may be expended”¹⁰
carve outlow impactHealth and Safety Code 130355(b)(1)
Three UC campuses (Merced, Santa Barbara, Santa Cruz) are not given an executive-committee seat. They could be represented only if the executive committee appoints them, and the categories for additional members in 130355(b)(2) are limited to institutions 'excluding the University of California' or 'not part of the University of California,' which appears to leave no path for those three campuses to be represented.
“The chancellors of the University of California campuses at Berkeley, Davis, Irvine, Los Angeles, Riverside, San Diego, and San Francisco shall each appoint a representative”¹⁰
conflictlow impactHealth and Safety Code 130358(g); 130357(b)
Funded research must be conducted under 'established standards of open scientific exchange' (130353(d), 130357(b)), yet funded institutions may require modifications to publications for patent 'or other reasons' and delay publication. Prepublication patent review is common in research agreements, but the open-ended 'other reasons' sits in some tension with the open-exchange requirement.
“Propose modifications to the publication or presentation for patent reasons or other reasons to be specified with reasonable particularity at that time.”¹⁰

Who benefits, as written

The single nonprofit medical research institute selected under Section 130353: Receives 50 percent of bond moneys, a $100 million General Fund start-up loan, consultation on council grant decisions, a participation offer on every grant, and the clearinghouse role over all commercialization agreements, while being exempt from public-agency laws.
“Fifty percent of the moneys shall be disbursed to a single nonprofit medical research institute”¹⁰
University of California, Los Angeles: Named to receive an offer to collaborate on clinical trials in every grant, and its council appointee is the first chairperson.
“The appointed representative from the University of California, Los Angeles shall serve as the first chairperson of the council.”¹⁰
Seven named UC campuses and the institutions they seat on the council: Their chancellors appoint the executive committee, which appoints the other members; only council-represented institutions may receive the grant half.
“shall accept or reject applications for funding received from those public and nonprofit universities and other nonprofit research institutions represented on the council”¹⁰
California patients, hospitals and insurers: Entitled to prices at least 20 percent below the national average for drugs or technologies developed with the funds, if commercialized.
“shall require that the technology or drug is made available to California patients, hospitals, and insurance companies at a price that is at least 20 percent below the national average price”¹⁰
State General Fund: Receives 10 percent of commercialization revenues until the full cost of the bonds, including interest, is repaid.
“shall be deposited into the General Fund until the cumulative amount of those payments equals the total cost to the state of the bonds”¹⁰
California suppliers: Grant recipients must make a good-faith effort to buy more than half of goods and services from California suppliers.
“in a good faith effort to achieve a goal of more than 50 percent of those purchases from California suppliers”¹⁰

Open questions in the text

Which existing organizations, if any, satisfy every criterion in Section 130353(a), and how would the department document that determination?
If criteria must be modified under 130353(b)(2), what process, notice, and public input would apply, and which criteria would be relaxed first?
Who calculates the national average price for the 20 percent California discount, and how is it enforced against manufacturers that license a funded technology but are not grant recipients?
Is the 10 percent state share calculated on gross or net revenue, and before or after shares owed to partner universities?
What limits, if any, apply to the institute's own administrative and overhead spending, given that the 98 percent purpose statement is not repeated in the operative text?
How are disputes resolved when the council and the institute disagree on a grant decision, or when the institute rejects a proposed licensing agreement?
Can bonds be issued to fund council grants if the institute does not request issuance under 130376(a)?
Can UC Merced, Santa Barbara, or Santa Cruz be represented on the council under the categories in 130355(b)(2)?

Limits: This reading assesses only the measure's text. It does not determine which institution would be selected, how the department would apply its discretion, or whether the research would produce revenue; those depend on facts outside the text. Statements about Government Code provisions are limited to what the measure itself cites.

Ask your own AI about this

Start a conversation in an assistant you use, already loaded with this page's research. Nothing goes from this site to those services until you click; after that, their privacy terms apply.

Open in Claude Open in ChatGPT Open in PerplexityDownload pack (.md)

Timeline

Newest first. Dated events reported by the sources, plus when each source was published.

2026-11-03Proposition 38 appears on the statewide general election ballot — California Secretary of State
2026-10-22Reporting cutoff for contribution totals — California Secretary of State
2026-10-20Published: This institute could get $4 billion from a ballot measure — LAist (republished from CalMatters)
2026-10-20Published: This institute could get $4 billion from a ballot measure. With just three workers, is it ready? — CalMatters
2026-10-20CalMatters published this report — CalMatters
2026-10-20Published: California Cancer Patients Disagree Over Whether Proposition 38 Will Help Them — KQED
2026-10-20KQED published this report — KQED
2026-10-20Published: Commentary: Voters to consider bond measure to fund limited medical research — Times of San Diego (republished from CalMatters)
2026-10-14Published: Prop. 38 explained: California voters to decide $8.4 billion medical research bond — ABC30
2026-10-14ABC30 published this explainer — ABC30
2026-10-14Published: Prop 38 asks: Should California take on more debt to fund a single field of medical research? (Dan Walters commentary) — CalMatters
2026-10-14Column published — CalMatters
2026-10-02Published: California's Proposition 38: What the Parkinson's community should know before Election Day — Michael J. Fox Foundation
2026-10-01Published: Proposition 38: Research bond (CalMatters 2026 Voter Guide) — CalMatters
2026-09-30Governor Newsom signed SB 895, according to MJFF — Michael J. Fox Foundation
2026-09-29Published: Prop. 38: The controversial billion-dollar bond measure for immunology research — LAist
2026-09-29Guide published (updated 2026-10-14) — LAist
2026-09-16Mazziotta told UC Regents the institute had hired three employees — CalMatters
2026-08-26Published: Proposition 38: Text of Proposed Laws — California Secretary of State
2026-08-25Published: Vote with the League: Quick Reference Guide, November 2026 — League of Women Voters of California
2026-08-10Published: Medical research nonprofit would be sole beneficiary of Prop 38 — KALW
2026-08-10KALW aired this report — KALW
2026-07-31Published: This CA proposition will send $4 billion to a single nonprofit. Who's behind it? — CalMatters
2026-07-31CalMatters published this analysis — CalMatters
2026-07-16Published: Proposition 38: Authorizes Bonds for Immunology Medical Research (LAO analysis) — Legislative Analyst's Office
2026-07-14Published: AAI-Endorsed California Immunology Research Initiative Qualifies for Ballot — American Association of Immunologists
2026-07Initiative qualified for the November 3, 2026 ballot — Hoover Institution
2026-06-29Published: KCA-Supported Immunology Research Initiative Advances to California's November Ballot — Kidney Cancer Association
2026-06Initiative qualified for the November 2026 ballot (reported June 29, 2026) — Kidney Cancer Association
2026-04-05Published: State ballot proposal would approve $8.4 billion in bonds to fund medical research — Daily Bruin
2026-04-05Kaplan quoted as saying he would vote for the initiative — Daily Bruin
2026-01-02Initiative entered circulation — Hoover Institution
2026-01-01Date by which the institute must own or lease a site of at least 200,000 square feet (Section 130353(a)(4)) — California Secretary of State
2026-01Proponents cleared to gather signatures — Daily Bruin
2025-01-01Cutoff date by which the selected institute must have existed and signed its UC affiliation agreement and bylaws (Section 130353(a)) — California Secretary of State
2024-08UCLA and CIII signed their formal affiliation agreement — CalMatters
2022CIII became a nonprofit — CalMatters

Official text & analysis

[8]2026-10-01 29 days ago

Proposition 38: Research bond (CalMatters 2026 Voter Guide)

CalMattersvoter guideNeutral

CalMatters' 2026 voter guide entry for Proposition 38. It summarizes the main arguments of supporters and critics, lists endorsements on each side, notes that no media outlets support it while four newspaper editorial boards oppose it, and reprints the official ballot text and fiscal impact.

Supporters say most diseases involve the immune system and that funding is needed because the Trump administration has tried to cut federal health research funding.
Critics fault the focus on one subset of biomedical research, question whether funded research can produce commercial drugs, question why one nonprofit gets half the money, and note $500 million to $600 million a year in debt payments for 20 years.
Listed support: American Association of Immunologists, California Democratic Party, City of Hope, Michelson Center for Public Policy.
Listed opposition: Robert Kaplan (Stanford), No on 38 led by California Health Policy Strategies, League of Women Voters, Orange County Register Editorial Board.
Media opposition listed: The Orange County Register, The San Diego Union-Tribune, The Sacramento Bee, San Francisco Chronicle; no media supporters listed.

Facts, claims & caveats

Supporting endorsers: American Association of Immunologists; California Democratic Party; City of Hope; Michelson Center for Public Policy
Opposing endorsers: Robert Kaplan; No on 38 (California Health Policy Strategies); League of Women Voters; Orange County Register Editorial Board
Opposing editorial boards: Orange County Register; San Diego Union-Tribune; Sacramento Bee; San Francisco Chronicle

Supporters say the potential for cures through immunotherapies is huge because most diseases involve the immune system.
Critics question whether research from the fund can produce commercial drugs given how hard it is to get a drug approved and brought to market.

Limits: A brief guide; arguments are summarized in a sentence or two, and the endorsement and campaign-finance lists reflect the page as captured, which may change. The campaign-finance figures did not load in the stored text.

References in this document:

Date from the page. Summary written 2026-10-28 in an operator-run Claude session. Link checked 2026-10-28.

[9]2026-09-29 31 days ago

Prop. 38: The controversial billion-dollar bond measure for immunology research

LAistvoter guideNeutral

LAist's voter guide to Prop. 38 (Robert Garrova), updated October 14, 2026. It explains the measure, the official ballot language and fiscal impact, the controversy over the apparent single beneficiary institute, and lists notable supporters and opponents.

Explains that about half the bond funds go to a UC-affiliated institute meeting specific criteria and half to competitive grants.
Opponents say the measure would seemingly steer $4.2 billion to one research group; CalMatters found only CIII would probably qualify, and backers say the criteria do not solely apply to it.
Notable supporters: Alzheimer's Los Angeles, Michael J. Fox Foundation, California Black Health Network.
Notable opposition: League of Women Voters of California, Orange County Register Editorial Board, Howard Jarvis Taxpayers Association.
Requires a simple majority to pass.

Facts, claims & caveats

Notable supporters: Alzheimer's Los Angeles; Michael J. Fox Foundation; California Black Health Network
Notable opponents: League of Women Voters of California; Orange County Register Editorial Board; Howard Jarvis Taxpayers Association
Vote needed: Simple majority

The Yes on 38 website says the $8.4 billion is 'vitally needed funding to advance breakthrough immunology research.'
The Vote No on Prop. 38 website says the measure could 'unfairly' steer $4.2 billion to one research organization.

Limits: A brief guide relying on CalMatters' analysis for the eligibility question; endorsement lists are selective.

References in this document:

Date stated in the document. Summary written 2026-10-28 in an operator-run Claude session. Link checked 2026-10-28.

[10]2026-08-26 2 months ago

Proposition 38: Text of Proposed Laws

California Secretary of Stateofficial textRecord

The complete Text of Proposed Laws for Proposition 38, the 'California Immunology Research and Cures Initiative,' from the Official Voter Information Guide (pages 123-133). It adds Division 110.5 (Sections 130350-130385) to the Health and Safety Code: Chapter 1 creates the research program (a single selected nonprofit institute receiving 50% of bond funds, a council-run grant program for the other 50%, revenue sharing, a California price discount, reporting, audits and oversight), and Chapter 2 is the $8.4 billion bond act. Sections 5-7 cover severability, liberal construction, and amendment limits.

Section 130352: 50% of fund moneys go to 'a single nonprofit medical research institute' and 50% to universities and nonprofit research institutions represented on the Advisory and Accountability Research Council, as individualized project grants.
Section 130353: the State Department of Public Health selects the institute using fixed criteria: a 501(c)(3) in existence by January 1, 2025, founded to specialize in immunology and immunotherapy; a UC campus affiliation agreement signed by January 1, 2025 with a campus whose health system exceeds 35,000 inpatient admissions and 3,500,000 outpatient visits a year; senior UC campus representatives on its board; a site of at least 200,000 square feet as of January 1, 2026; $250 million in identified philanthropic funding; and $50 million commitments each for a rapid vaccine program and a microbiome program. If no institute qualifies, the department must modify the criteria minimally.
Section 130353(e) appropriates $100 million from the General Fund as start-up loans to the institute, to be repaid from bond proceeds.
At least $2.1 billion from each half must go to research on cancer, heart disease and Alzheimer's; state administrative costs are capped at 2%.
Section 130355: the council's seven-member executive committee is appointed by the chancellors of UC Berkeley, Davis, Irvine, Los Angeles, Riverside, San Diego and San Francisco; the UCLA representative is the first chair; the executive committee appoints 10 to 15 more members from non-UC institutions.
Section 130357: grantees must offer the selected institute the opportunity to collaborate on funded research and must offer UCLA by name the opportunity to collaborate on clinical trials; indirect costs are capped at 20%; grantees must aim for over 50% California suppliers.
Section 130358: recipients pay the state 10% of revenues from commercializing funded intellectual property until bond costs are repaid, then into the research fund; licensed products must be sold in California at least 20% below the national average price; the institute runs the licensing program and acts as a clearinghouse for all commercialization agreements.
Section 130363: the institute 'shall not be deemed a public agency for any purpose under state law,' including the Public Records Act, the Bagley-Keene open meeting act, and the Political Reform Act; the council is covered by the Political Reform Act with stated exceptions.
Section 130376: bonds are issued upon written request by the selected institute, through the department, to the Finance Committee (Treasurer, Controller, Director of Finance).
Section 7: the Legislature may amend only by two-thirds vote to further the act's purposes, and may not amend the allocation and disbursement of bond proceeds or their permitted purposes.

Facts, claims & caveats

Statute added: Health and Safety Code Division 110.5, Sections 130350-130385
Bond authorization: $8,400,000,000 (Section 130372)
Institute share: 50% to a single nonprofit medical research institute (Section 130352(b)(1))
Grant share: 50% to council-represented institutions (Section 130352(b)(2))
Disease earmark: At least $2.1 billion of each half for cancer, heart disease, Alzheimer's (Section 130354)
Administrative cap: 2% of moneys disbursed (Section 130354(a)(3))
Start-up loan: $100 million General Fund appropriation to the institute (Section 130353(e))
Revenue share: 10% of commercialization revenues to the state (Section 130358(a))
California price: At least 20% below the national average price excluding California (Section 130358(b))
Minimum royalty: 10% of gross revenues; department may approve as low as 5% (Section 130358(f))
Indirect cost cap: 20% of a research grant (Section 130357(g))
Amendment: Two-thirds legislative vote; allocation of bond proceeds not amendable (Sec. 7)

The measure's findings declare that immunology and immunotherapy, if adequately funded, will lead to an explosion of scientific progress, and that 99.4 percent of new drugs approved by the FDA between 2010 and 2019 resulted from publicly funded research.
The measure's purpose section states that the 10 percent revenue requirement makes this 'effectively a loan program' ensuring taxpayers 'will fully recoup their investment.'

Limits: This is the legal text itself and does not say which institution would qualify. The stored copy is converted from the PDF, so italics marking new text are lost, and the file also contains the end of Proposition 37 and the start of Proposition 39 from adjacent pages, which are not part of this measure.

Date from the page. Summary written 2026-10-28 in an operator-run Claude session. Link checked 2026-10-28.

[14]2026-07-16 3 months ago

Proposition 38: Authorizes Bonds for Immunology Medical Research (LAO analysis)

Legislative Analyst's Officeofficial analysisNeutral

The Legislative Analyst's Office's official ballot analysis of Proposition 38. It explains medical research funding, describes the measure's institute, grant council, revenue-sharing and discount provisions, and estimates fiscal effects: a General Fund cost of $500 million to $600 million a year for about 20 years, uncertain but potentially significant offsetting revenue that could take decades, and uncertain indirect effects on state health program costs.

Prop. 38 allows an $8.4 billion general obligation bond for immunology and immunotherapy research, repaid from the General Fund.
At least $4.2 billion must be used for immunology research on cancer, heart disease and Alzheimer's; no more than 2% for state administration.
About half the funds go to a research institute selected by the California Department of Public Health that meets criteria on size, funding and collaboration with a UC campus.
A council of representatives from 7 UC campuses and 10 to 15 other institutions would award the other half as competitive grants among its member organizations.
Ten percent of revenue from discoveries goes first to the General Fund until bond costs are repaid, then to further research.
The annual cost is about 0.25% of the General Fund budget; total cost is about 10% more after inflation than paying cash.
Earlier voter-approved stem cell bonds (Prop. 71 of 2004 and Prop. 14 of 2020) together authorized $8.5 billion.

Facts, claims & caveats

Bond amount: $8.4 billion general obligation bond
Annual repayment: $500 million to $600 million for about 20 years
Share of General Fund: About 0.25% per year
Cost vs. cash after inflation: About 10% more
Disease earmark: At least $4.2 billion for cancer, heart disease, Alzheimer's
Prior research bonds: Prop. 71 (2004) and Prop. 14 (2020), $8.5 billion combined
U.S. medical R&D funding in 2023: About $300 billion

The LAO estimates the state could receive revenue from funded research, an amount it calls uncertain but potentially significant, with timing that could take decades.
The LAO states the overall effect on state health program costs, such as Medi-Cal, is uncertain because new treatments could raise or lower average patient care costs.

Limits: A fiscal and descriptive analysis; it does not evaluate which institute would qualify or whether the research would succeed. Revenue offsets are estimated only qualitatively.

Date from the page. Summary written 2026-10-28 in an operator-run Claude session. Link checked 2026-10-28.

[18]Undated

Proposition 38: Authorizes Bonds for Immunology Medical Research. Initiative Statute. (Official Voter Information Guide)

California Secretary of Statevoter guideNeutral

The Secretary of State's Official Voter Information Guide summary page for Proposition 38. It gives the official summary (an $8.4 billion general obligation bond for immunology and immunotherapy research, half to a single University of California-affiliated nonprofit research institute and half to research grants), the fiscal impact line, the listed supporters and opponent, what yes and no votes mean, and short pro and con statements from the campaigns.

Put on the ballot by petition signatures as an initiative statute.
Official summary: $8.4 billion in bonds, half to a single UC-affiliated nonprofit medical research institute, half to research grants.
Fiscal impact: increased state cost of $500 million to $600 million annually for about 20 years, with some or all of the cost offset if funded research generates revenue.
Listed supporters: Michael J. Fox Foundation; Alzheimer's Los Angeles; Kidney Cancer Association; American Nurses Association\California. Listed opponent: Robert M. Kaplan, Ph.D.
Contact for the yes side is the committee 'YES on 38: Californians for Life-Saving Immunology Research and Cures'; the no side contact is Kaplan at Stanford's Clinical Excellence Research Center.

Facts, claims & caveats

Bond amount: $8.4 billion
Allocation: Half to a single UC-affiliated nonprofit institute, half to research grants
Fiscal impact: $500 million to $600 million annually for about 20 years
Measure type: Initiative statute, qualified by petition signatures
Supporters listed: Michael J. Fox Foundation; Alzheimer's Los Angeles; Kidney Cancer Assoc; American Nurses Assoc\CA
Opponent listed: Robert M Kaplan Ph.D.

Supporters state that Prop. 38 supports life-saving immunology research to cure and prevent diseases like cancer, heart disease and Alzheimer's, includes independent audits, mandates a 20% prescription discount, and is designed to ensure no cost to taxpayers.
The opponent states that Prop. 38 would commit taxpayers to decades of new bond debt, limit California's flexibility to address changing health priorities, and that research funding should go through the normal budget process rather than ballot initiatives.

Limits: A summary page only; the pro and con statements are the campaigns' own words and are not checked for accuracy. For the operative provisions, read the Text of Proposed Laws; for fiscal detail, the Legislative Analyst's analysis.

References in this document:

Yes on 38 campaign website

Summary written 2026-10-28 in an operator-run Claude session. Link checked 2026-10-28.

[20]Undated

Text of Proposed Law: Proposition 38 (Official Voter Information Guide, Text of Proposed Laws, PDF pages 24–34)

California Secretary of Stateofficial textRecord

Not summarized: same official text as the summarized per-proposition SoS PDF. See the original.

Link checked 2026-10-29.

[21]Undated

Proposition 38: Arguments and Rebuttals

California Secretary of Statevoter guideMixed

The official ballot arguments and rebuttals for Proposition 38 from the Secretary of State's voter guide. The argument in favor, signed by representatives of Alzheimer's Los Angeles, the ALS Association and the Kidney Cancer Association, stresses life-saving research, federal funding cuts, a 20% patient discount, and a claim of no net cost. The argument against, by Robert M. Kaplan, Ph.D., objects to ballot-box research priorities, bond financing of research, and the revenue assumptions, and points to a proposed state research agency as an alternative.

Supporters list the Alzheimer's Association, Michael J. Fox Foundation, American Nurses Association\California, ALS Association, National Multiple Sclerosis Society and Prostate Cancer Foundation, among others.
Supporters say at least half of funds go to cancer, heart disease and Alzheimer's research and that the measure offsets federal research funding cuts.
Supporters say Prop. 38 is designed to pay for itself 'WITH NO NET COST TO THE STATE OR TAXPAYERS' through the 10% licensing revenue return.
Kaplan argues research priorities should be set by scientific review and public health planning, not election campaigns, and that 'ballot-box science' favors the most visible topics.
Kaplan argues bonds suit long-lived infrastructure, not research, and that universities rarely commercialize therapies themselves, so returns seldom flow to the state treasury.
Kaplan argues the California price discount could lead companies to prioritize sales in other states.
Kaplan cites a proposal by Senator Scott Wiener for a state research agency modeled on NIH and NSF as an alternative.

Facts, claims & caveats

Argument in favor signers: Susan Disney Lord (Alzheimer's Los Angeles); Eugene P. Brandon, Ph.D. (ALS Association); Dr. Brian Shuch (Kidney Cancer Association)
Rebuttal to argument against signers: Andrew Dale; Anne M. Holloway (Michael J. Fox Foundation); Chris Tarver, R.N. (American Nurses Association\California)
Argument against signer: Robert M Kaplan, Ph.D.
Repayment figure cited by opponent: About $500 million a year for about 25 years, attributed to the LAO

Supporters claim any cure or immunotherapy developed through Prop. 38 must be provided to California patients at a 20% discount and that preventing disease will save tens of billions of dollars.
Supporters claim for-profit corporations are not eligible for grant funding and that the measure has a 2% administrative cap, public disclosure and independent audits.
Kaplan claims the pay-for-itself argument is speculative and that California faces a continuing structural budget deficit.
Kaplan claims the measure earmarks billions for one scientific field regardless of future needs, and that other conditions such as mental illness and kidney disease also deserve attention.

Limits: These are advocacy statements by each side; the guide notes they have not been checked for accuracy by any official agency.

Summary written 2026-10-28 in an operator-run Claude session. Link checked 2026-10-28.

Third-party analysis

[4]2026-10-20 10 days ago

Commentary: Voters to consider bond measure to fund limited medical research

Times of San Diego (republished from CalMatters)third party analysisStance unknown

Not summarized: verbatim reprint of a summarized CalMatters article. See the original.

Date from the page. Link checked 2026-10-28.

[6]2026-10-14 16 days ago

Prop 38 asks: Should California take on more debt to fund a single field of medical research? (Dan Walters commentary)

CalMattersthird party analysisOpposes

A CalMatters opinion column by Dan Walters that places Prop. 38 in the history of California's stem cell bonds (Props. 71 and 14) and questions bond-funding one field of research. It cites CalMatters' finding that the Michelson-founded institute would be the only qualifier for half the money and argues bonds are loans that displace other spending.

Recounts that Prop. 71 (2004) created the California Institute for Regenerative Medicine with $3 billion in bonds and Prop. 14 (2020) added $5.5 billion, with no independent analysis of results, in Walters' description.
Cites CalMatters' finding that CIII, founded and headed by Gary Michelson, would be the only organization qualifying for half the money.
Attributes to the LAO an estimate of about $500 million a year for 25 years, about $12.5 billion total.
Notes SB 895 places a $7.5 billion bond for a new California Foundation for Science and Health Research on the 2028 ballot.

Facts, claims & caveats

Repayment cited: About $500 million a year for 25 years, about $12.5 billion
Related measure: SB 895: $7.5 billion bond on the 2028 ballot

Walters argues issuing bonds to support one avenue of medical research is 'a questionable activity regardless of cost.'
Walters argues bond repayments have the highest legal priority and displace funds for education, healthcare and other services.
Walters writes that if the state has a role in research, all fields should be explored, 'not merely pet projects and organizations that some billionaire patrons have chosen.'

Limits: An opinion column, not news reporting. The repayment estimate it cites links to an LAO document dated 2025, before the measure qualified. The same column was republished by Times of San Diego.

References in this document:

Date stated in the document. Summary written 2026-10-28 in an operator-run Claude session. Link checked 2026-10-28.

[7]2026-10-02 28 days ago

California's Proposition 38: What the Parkinson's community should know before Election Day

Michael J. Fox Foundationthird party analysisSupports

A Michael J. Fox Foundation policy news post explaining Prop. 38 to the Parkinson's community. MJFF says it is a member of the coalition supporting the measure and argues it could advance research relevant to Parkinson's, while noting the measure is not solely focused on Parkinson's.

MJFF is a member of the statewide coalition supporting Prop. 38.
Says the measure would dedicate $8.4 billion to immunology research at California universities and nonprofits and include affordability provisions.
Cites nearly 135,000 Californians living with Parkinson's and atypical parkinsonisms.
Notes MJFF also supported SB 895, a state health and science research fund that it says will appear on the March 2028 ballot.

Facts, claims & caveats

Californians with Parkinson's cited: Nearly 135,000
Related bill: SB 895, signed September 30, 2026, per MJFF

MJFF Chief Policy Officer Dan Feehan said, 'Proposition 38 will help accelerate research that turns discoveries into breakthroughs for people living with Parkinson's and many other diseases.'

Limits: An advocacy post from a supporting organization; it does not discuss criticisms, costs or the institute allocation.

References in this document:

Date stated in the document. Summary written 2026-10-28 in an operator-run Claude session. Link checked 2026-10-28.

[11]2026-08-25 2 months ago

Vote with the League: Quick Reference Guide, November 2026

League of Women Voters of Californiathird party analysisOpposes

The League of Women Voters of California's November 2026 quick reference guide. It recommends a No vote on Prop. 38 in one paragraph.

LWVC position on Prop. 38: OPPOSE.
Reasoning: medical research saves lives but bonds are a poor way to fund it; repayment of $500 million to $600 million a year for about 20 years, about 10 percent more after inflation than paying up front.
Also says it would lock billions into one field as other research needs emerge and that the stem-cell bond experience shows royalties may do little to offset debt.

Facts, claims & caveats

LWVC recommendation: Oppose Prop. 38

The League argues bonds are a poor way to fund medical research.
The League argues California's stem-cell bond experience shows royalties may do little to offset the debt.

Limits: A one-paragraph advocacy recommendation; most of the document concerns other measures.

References in this document:

LWVC full ballot recommendations

Date from the page. Summary written 2026-10-28 in an operator-run Claude session. Link checked 2026-10-28.

[15]2026-07-14 3 months ago

AAI-Endorsed California Immunology Research Initiative Qualifies for Ballot

American Association of Immunologiststhird party analysisSupportslink dead

Not yet summarized; see the original.

Date from search listing. Link checked 2026-10-28.

[16]2026-06-29 4 months ago

KCA-Supported Immunology Research Initiative Advances to California's November Ballot

Kidney Cancer Associationthird party analysisSupports

A Kidney Cancer Association blog post announcing that the immunology initiative qualified for the November 2026 ballot and that KCA supports it. It lists the initiative's key provisions as described by the campaign coalition and quotes KCA leaders.

KCA signed on in support of the initiative.
Describes provisions: $8.4 billion for California public and nonprofit institutions, half for cancer, heart disease and Alzheimer's, 10% licensing revenue returned to the state, a 2% admin cap, and a minimum 20% discount for Californians.
KCA board member Dr. Brian Shuch, a UCLA kidney cancer program director, says federal funding cuts have slowed promising cancer trials.
Notes the defense-backed Kidney Cancer Research Program was cut from $50 million to $0 and partially restored to $15 million for fiscal 2026.

Facts, claims & caveats

Kidney Cancer Research Program funding: Cut from $50 million to $0, restored to $15 million as of FY2026

KCA President and CEO Gretchen E. Vaughan said immunotherapies have helped extend the lives of kidney cancer patients.
Dr. Brian Shuch said, 'Federal funding cuts and uncertainty have already slowed promising cancer trials and put junior investigators' careers at risk.'
The coalition claims the measure would generate tens of billions of dollars in economic value and tens of thousands of jobs.

Limits: An advocacy post that relays the campaign's description of the measure; it does not address criticisms, costs or the institute allocation.

References in this document:

Coalition press release on qualification

Date stated in the document. Summary written 2026-10-28 in an operator-run Claude session. Link checked 2026-10-28.

[19]Undated

CA Decides: Prop 38, Immunology and Immunotherapy Research Bond

Hoover Institutionthird party analysisNeutral

The Hoover Institution's 'California Decides' explainer on Prop. 38. It lays out what the measure does, quotes key legal language, identifies Gary K. Michelson as the proponent, and weighs the cost of borrowing against uncertain returns, drawing on the stem cell bond precedent. It lists potential benefits and risks and open questions, without a recommendation.

Identifies Dr. Gary K. Michelson as the filer and financier of the initiative (AG No. 25-0026A1); it entered circulation January 2, 2026 and qualified in July 2026.
States the LAO estimates about $500 million a year for roughly 25 years, about $12.5 billion total.
Says the stem cell program produced real scientific value but minimal direct financial return to the state, with only a few hundred thousand dollars received from funded inventions by the early 2020s under Prop. 71.
Notes the seven UC chancellors are at the center of the grant council, raising the same grant-maker/grant-seeker closeness questions that dogged the stem cell agency.
Presents the counterargument that basic research is a public good underfunded by markets and that the 20% discount and 2% admin cap respond to stem cell program criticisms.
Open questions include which institute would be selected and whether the criteria effectively pre-decide it, and how enforceable the price discount would be.

Facts, claims & caveats

Initiative number: AG No. 25-0026A1
Signatures required: 546,651
Entered circulation: 2026-01-02
Repayment cited: About $500 million a year for roughly 25 years, about $12.5 billion
Prior research bonds: Prop. 71 (2004) $3 billion; Prop. 14 (2020) $5.5 billion

The proponent argues immunology is on the brink of transformative breakthroughs and that dedicated funding would keep California at the front of that science.
Opponents, as Hoover describes them, question whether the state should borrow at this scale for research that federal agencies, universities and private capital already fund.
Hoover writes that the LAO is 'blunt' that revenue is uncertain and could take decades.

Limits: A think-tank explainer with its own framing; its potential risks and open questions are Hoover's own assessment, and its stem cell revenue figures are given without a detailed citation in the text.

References in this document:

Summary written 2026-10-28 in an operator-run Claude session. Link checked 2026-10-28.

Money

[22]Undated

Proposition 38 contribution totals

California Secretary of Statecampaign financeRecord

The Secretary of State's ballot measure contribution totals for Prop. 38, through October 22, 2026. Support committees reported $71,229,216; the one opposition committee reported $11,990.

Support total: $71,229,216 through 10/22/2026.
Michelson Center for Public Policy, Inc. - Yes on 38 (a 501(c)(4)): $13,000,000.
Yes on 38: Californians for Life-Saving Immunology Research and Cures, Sponsored by the Michelson Center for Public Policy: $58,229,216.
Opposition: No on Proposition 38, $11,990.

Facts, claims & caveats

Total support contributions: $71,229,216
Total opposition contributions: $11,990
Reporting date: Through 2026-10-22
Committee 1494727: Michelson Center for Public Policy, Inc. - Yes on 38: $13,000,000
Committee 1485847: Yes on 38: Californians for Life-Saving Immunology Research and Cures: $58,229,216
Committee 1495405: No on Proposition 38: $11,990

Limits: Totals only; it does not list individual donors, and amounts may include loans. Totals are cumulative through the stated date and will change.

References in this document:

Summary written 2026-10-28 in an operator-run Claude session. Link checked 2026-10-28.

News & other

[1]2026-10-20 10 days ago

This institute could get $4 billion from a ballot measure

LAist (republished from CalMatters)newsNeutral

Not summarized: verbatim reprint of a summarized CalMatters article. See the original.

Date from the page. Link checked 2026-10-28.

[2]2026-10-20 10 days ago

This institute could get $4 billion from a ballot measure. With just three workers, is it ready?

CalMattersnewsNeutral

CalMatters reporting (Mikhail Zinshteyn) on the readiness of the California Institute for Immunology and Immunotherapy (CIII), which earlier CalMatters reporting found is the only institute currently meeting Prop. 38's criteria for the $4.2 billion half of the bond. Based on public records and UC Regents remarks, it reports the institute had three employees versus a plan for about 51, describes its UCLA affiliation agreement and facility timeline, quotes the Yes campaign, and covers the measure's exemption of the institute from state transparency laws.

As of September 2026 the institute had three employees (a chief operating officer, a general counsel and a scientific advisor), versus about 51 planned by summer 2025, according to UCLA Health CEO John Mazziotta at the Sept. 16 UC Regents meeting.
The 2024 UCLA affiliation agreement requires the institute to pay UCLA 7.5% of net revenue from drugs and technologies developed by its staff; the institute leases 235,000 square feet at a UCLA research park.
The research park is not expected to be fully built until at least late 2028; construction costs still need roughly $100 million, Mazziotta said.
Yes on 38 spokesperson Robin Swanson said at a September press conference it is 'very likely' CIII will qualify for half the funds, and later that it won't get bond money if it isn't ready; the Department of Public Health makes the final decision.
Prop. 38 exempts the selected institute from the Public Records Act, open meetings laws and the Political Reform Act; campaign spokesperson Claudia Briggs said applying those laws to private organizations would 'not fit well.'
Gov. Newsom, the California Democratic Party, the state GOP and the union of graduate students and postdoctoral researchers have endorsed Prop. 38.
Support money exceeds $66 million, including at least $61.2 million from Gary Michelson and his policy institute (about $14 million in loans); the no side had raised about $8,800.

Facts, claims & caveats

CIII employees, Sept 2026: 3
Planned employees by summer 2025: About 51
Revenue share to UCLA under affiliation agreement: 7.5% of net revenue
Leased research space: 235,000 square feet (per institute)
Spending to date: $20 million (per Mazziotta)
Pro-side fundraising: More than $66 million, at least $61.2 million from Michelson and his policy center
No-side fundraising: About $8,800
Endorsers named: Gov. Gavin Newsom; California Democratic Party; state GOP; graduate student and postdoc union

CalMatters reports that public statements and records raise questions about how prepared the institute is to manage the money.
Critics quoted say Prop. 38 is well-intentioned but poorly designed because it overlooks established public and nonprofit labs and that California should fund research more broadly.
Backers say state bond money is needed to stabilize research funding after the Trump administration repeatedly attempted to cut federal science grants.
Swanson (Yes on 38) wrote that the institute won't get bond money if it isn't ready to begin work, 'plain and simple.'

Limits: Investigative news based on records and officials' statements at a point in time; staffing and facility status may change. The institute declined to answer questions about staffing, and Michelson declined an interview.

References in this document:

Date stated in the document. Summary written 2026-10-28 in an operator-run Claude session. Link checked 2026-10-28.

[3]2026-10-20 10 days ago

California Cancer Patients Disagree Over Whether Proposition 38 Will Help Them

KQEDnewsNeutral

KQED reporting (April Dembosky) on patients divided over Prop. 38. Supporters include a lymphoma survivor whose CAR-T immunotherapy put her in remission and an Alzheimer's caregiver; opponents include a Parkinson's patient and other retired Legislative Analyst's Office analysts who argue the measure is narrow, opaque, expensive and unlikely to pay for itself.

Laurie Adami, in complete remission after a CAR-T trial, supports the measure so more patients can access such treatments.
KQED notes only 15 to 20% of patients achieve durable results from immunotherapy and only 14% of drugs in clinical trials reach FDA approval.
Former LAO health section head Dan Carson said the state received just $16 million of $6 billion promised from the stem cell bond and that Prop. 38 won't pay for itself.
Marianne O'Malley, a former LAO analyst with Parkinson's, said the measure steers funds to a billionaire's project and waives transparency laws.
Former LAO analyst Judy Heiman said research grants should be openly competitive and merit-based, pointing to a broader research bond on the March 2028 ballot.
KQED reports state taxpayers would owe about $4 billion in interest on top of the $8.4 billion bond.

Facts, claims & caveats

Interest cost cited: About $4 billion on top of $8.4 billion
Durable immunotherapy response rate cited: 15 to 20% of patients
Clinical-trial drugs reaching approval: 14%
Stem cell bond royalties cited by Carson: $16 million

Adami said, 'Why wouldn't I want more patients to be able to access the type of treatment that finally saved my life?'
O'Malley said the measure 'hijacks the initiative process to steer public funds to a billionaire's philanthropic project.'
Carson said that after reviewing the fine print, the measure will not pay for itself, 'Not even close.'
Robert Kaplan said Prop. 38 money is good for California institutions but California taxpayers might bear a disproportionate share of research costs.

Limits: Built on individual patient perspectives; several opponents quoted are former LAO analysts speaking personally, not for the LAO. Read to the end of the article text; the rest of the stored page is site script data.

References in this document:

Long document: only the first 9,848 characters were summarized.

Date stated in the document. Summary written 2026-10-28 in an operator-run Claude session. Link checked 2026-10-28.

[5]2026-10-14 16 days ago

Prop. 38 explained: California voters to decide $8.4 billion medical research bond

ABC30newsNeutral

ABC30 (KABC) explainer by Josh Haskell quoting both campaigns. The Yes side frames Prop. 38 as filling gaps from federal research cuts; the No side calls it a bad deal benefiting an institute founded by its billionaire backers, Gary K. Michelson and Meyer Luskin.

Robin Swanson (Yes on 38) says the Trump administration has cut billions from NIH and proposed $5 billion more in cuts for 2027.
David Panush (No on 38) calls it 'a bad deal for taxpayers, it's bad policy, bad science.'
Panush says the institute lacks an address, phone number, executive director or researchers on staff.
Swanson says lots of institutes will qualify for funding but it is 'very likely' CIII will qualify for half under current criteria, with the Department of Public Health deciding.

Facts, claims & caveats

Yes campaign spokesperson: Robin Swanson
No campaign spokesperson: David Panush
Institute co-founders named: Gary K. Michelson and Meyer Luskin

Swanson: 'Prop. 38 is positioned to fill that gap and position California as a world leader in biomedical research.'
Panush: 'we need to send a message to future billionaires that California voters can't be bought.'
Swanson: 'it's not accurate to say that only one institute would qualify for funds under this measure.'

Limits: A short TV news piece consisting mostly of campaign quotes; it does not independently verify the claims.

Date from the page. Summary written 2026-10-28 in an operator-run Claude session. Link checked 2026-10-28.

[12]2026-08-10 2 months ago

Medical research nonprofit would be sole beneficiary of Prop 38

KALWnewsNeutral

A short KALW radio item based on CalMatters reporting (Mikhail Zinshteyn) that Prop. 38 would designate half its funds to one unnamed institute whose criteria appear to fit only the California Institute for Immunology and Immunotherapy, co-founded by the measure's primary backer Gary K. Michelson.

About $4 billion would go to one unnamed institute meeting very specific criteria, including UC affiliation with a high-volume medical center.
Only CIII, based in a UCLA research park, appears to meet the criteria.
Cal State Fullerton political scientist Sarah Hill says it is 'very clearly designed to support a specific nonprofit.'

Facts, claims & caveats

Institute named: California Institute for Immunology and Immunotherapy (UCLA research park)

Sarah Hill said, 'It is very clearly designed to support a specific nonprofit.'
Skeptics wonder whether it is fair to commit so much money to one institute in a state with many medical researchers.

Limits: A brief broadcast summary of CalMatters' reporting; it includes no response from the Yes campaign.

Date stated in the document. Summary written 2026-10-28 in an operator-run Claude session. Link checked 2026-10-28.

[13]2026-07-31 3 months ago

This CA proposition will send $4 billion to a single nonprofit. Who's behind it?

CalMattersnewsNeutral

CalMatters analysis (Mikhail Zinshteyn) concluding that Prop. 38's institute criteria very likely exclude every institute except the California Institute for Immunology and Immunotherapy (CIII), whose co-founder and board chair Gary K. Michelson is the measure's chief backer. It walks through each criterion against public records, quotes a political scientist and opponent Robert Kaplan, and gives the Yes campaign's response that the criteria are not tailored to one institute.

Only UCLA's health system exceeds 3.5 million outpatient visits a year (4.1 million in 2025; UCSF 3.4 million), so only a UCLA-affiliated institute currently meets that criterion, per UC's fiscal audit.
A UCLA spokesperson, Phil Hampton, confirmed only CIII among UCLA-affiliated nonprofits could satisfy the criteria.
Michelson and his wife donated $50 million to two research programs whose descriptions nearly match the measure's rapid vaccine and microbiome criteria; CIII reportedly received $250 million in philanthropy, matching the $250 million criterion.
Four senior UCLA administrators, including Chancellor Julio Frenk, sit on CIII's board, matching the board-composition criterion.
Michelson has given CIII at least $120 million since 2022; Michelson and his Michelson Center for Public Policy gave at least $8.2 million to the Yes campaign, and co-founder Meyer Luskin at least $5 million (as of this report).
The grant council is chosen by chancellors of seven UC campuses (excluding Merced, Santa Barbara, Santa Cruz); grant applicants must come from council-represented employers, and the council must confer with the institute on final decisions.
Yes on 38 spokesperson Claudia Briggs said the language isn't uniquely tailored to CIII and the criteria ensure a well-prepared, UC-connected institute.

Facts, claims & caveats

UCLA outpatient visits, 2025: 4.1 million
UCSF outpatient visits: 3.4 million
Michelson gifts to CIII: At least $120 million since 2022
Michelson and center to Yes campaign: At least $8.2 million (as of July 2026)
Meyer Luskin to Yes campaign: At least $5 million
UC campuses excluded from council: Merced, Santa Barbara, Santa Cruz
Disclosure: The Michelson Center for Public Policy has given $1,000 to $9,900 to CalMatters

Sarah Hill, Cal State Fullerton political scientist, said 'It is very clearly designed to support a specific nonprofit' and that the language is 'oddly specific with numbers.'
Robert Kaplan, former NIH associate director, said tracking a huge portion to one institution is 'a bad idea' given immunology talent across California.
Briggs (Yes on 38) wrote, 'We wrote the measure to ensure a highly qualified nonprofit could receive funding,' and cited UCLA's size and Los Angeles location to explain UCLA's role.
CalMatters attributes to the LAO an estimate of $500 million annually for 25 years, more than $12 billion total.

Limits: An analysis of eligibility at the time of reporting; it notes the measure lets the Department of Public Health modify the criteria if no institute qualifies. The repayment estimate it cites links to an LAO document dated 2025, before the measure qualified. Campaign-finance figures are as of July 2026.

References in this document:

Date stated in the document. Summary written 2026-10-28 in an operator-run Claude session. Link checked 2026-10-28.

[17]2026-04-05 6 months ago

State ballot proposal would approve $8.4 billion in bonds to fund medical research

Daily BruinnewsNeutral

Daily Bruin (UCLA student newspaper) report from the signature-gathering stage of the immunology initiative. It summarizes the proposal, notes supporting nonprofits, and quotes UCLA researchers, including Robert Kaplan, who at the time said he would vote for it while raising concerns about repayment and the price discount.

Describes the initiative as $8.4 billion in bonds, half for Alzheimer's, cancer and heart disease, split between a UC-affiliated institute and a grant program.
Cites the LAO's estimate of about $500 million a year over 25 years.
Lists Blood Cancer United, the Parkinson Association of Northern California and the California Black Health Network among groups leading the effort.
Robert Kaplan said he would vote for the initiative but called the assumption of rapid repayment 'completely unrealistic' and worried the discount could deter companies from selling in California.
Notes a separate UC-sponsored bill for a $23 billion research bond (SB 895 as then proposed).

Facts, claims & caveats

Signatures required: 546,651
Signature verification deadline: 2026-06-25
Repayment cited: About $500 million a year over 25 years

Adam Zarrin of Blood Cancer United said the measure 'will strengthen California's research and clinical trial infrastructure.'
Kaplan said, 'The assumption that there will be a rapid turnaround that will result in the repayment of this investment in the short term is completely unrealistic.'
Burt Cowgill of the UCLA Fielding School said the initiative is an opportunity to continue supporting California-based research but that added state taxes could be a challenge.

Limits: Written before the measure qualified and before Kaplan became the official ballot opponent; his April position differs from his later published argument against. Mentions of the separate $23 billion bill describe a version later changed.

References in this document:

Daily Bruin: UC sponsors $23 billion research bond bill

Date stated in the document. Summary written 2026-10-28 in an operator-run Claude session. Link checked 2026-10-28.